Related Experiment Video
Updated: Jun 21, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin
Jung Sun Kim1, Sang Yup Lim2, Jinwook Hwang3
1Division of Hematology/Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Abstract:
Primary pericardial malignant mesothelioma (PPM) is a very rare malignancy, with an incidence of less than 0.002% and represents less than 5% of all mesotheliomas. The cause of pericardial mesothelioma is uncertain that differ from pleural mesothelioma which is associated with asbestos exposure. This malignancy is terribly aggressive and has very poor prognosis with less than six months of overall survival. We present a case of a 71-year-old woman who was diagnosed with cardiac tamponade caused by PPM and received chemotherapy with pemetrexed and cisplatin for six months. During two years she was alive without disease progression. To better understand the clinical, pathologic features and treatment outcome of this entity, we reviewed 23 cases described in the English literature from 2009, together with our case, provided a total of 24 cases. Based on this review, we suggest that PPM must be considered in patients who have unexplained massive pericardial effusion and recommend chemotherapy with pemetrexed and cisplatin for the better outcome of PPM.
Insights
Primary pericardial malignant mesothelioma (PPM) is a rare and aggressive cancer. Chemotherapy with pemetrexed and cisplatin showed promising results in a case study and literature review.
Area of Science:
- Oncology
- Pathology
Background:
- Primary pericardial malignant mesothelioma (PPM) is an extremely rare cancer, accounting for less than 5% of all mesotheliomas.
- Unlike pleural mesothelioma, the cause of PPM is not clearly linked to asbestos exposure.
- PPM is characterized by aggressive behavior and a very poor prognosis, with a median survival of less than six months.

